Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
John B Zuchero · STANFORD UNIVERSITY · 2021 · $432,982 — PROJECT SUMMARY Recent successes in RNA medicine, including the first-in-class Spinraza treatment for spinal muscular atrophy, demonstrate RNA gain-of-function as a novel therapeutic modality for previously intractable neurological disease and raise the prospect of similar treatments for demyelinati…
Patricia DEVAUX · MAYO CLINIC ROCHESTER · 2021 · $318,000 — Abstract. The recent advances in induced pluripotent stem cells (iPSCs) and gene therapy tools have opened up a new avenue to study and treat diseases, particularly of disorders with defective bone marrow. Bone marrow failure syndromes (BMFS) are characterized by reduced blood cells due to a dysfunc…
Paul Bates · UNIVERSITY OF PENNSYLVANIA · 2021 · $548,028 — Severe Fever with Thrombocytopenia Syndrome virus (SFTSV) is a pathogenic, tick-transmitted bunyavirus that can cause a severe febrile hemorrhagic-like disease with case fatality rates of up to 30%. Discovered during a 2009 outbreak of febrile illness in China, the geographic distribution of SFTSV e…
Li Wu · UNIVERSITY OF IOWA · 2021 · $193,125 — Abstract The COVID-19 pandemic caused by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has resulted in global health and economic crises. To develop effective vaccines and antivirals to prevent and control SARS-CoV-2 or other coronavirus infections, it is critical to understan…
Roger L Shapiro · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2021 · $1,340,804 — Overall Project Summary/Abstract Antiretroviral treatment (ART) options for pregnant women and children living with HIV have fallen behind those for adults, reflecting the substantial research gap for modern ART regimens in these groups. Safety and efficacy studies of specific ART regimens in pregna…
Karen L. Kotloff · UNIVERSITY OF MARYLAND BALTIMORE · 2021 · $1,585,845 — Project Summary/Abstract The University of Maryland School of Medicine (UMSOM) Center for Vaccine Development and Global Health (CVD) has been an established VTEU site since 1974. The goal of the VTEUs is to initiate innovative concepts for clinical research and implement clinical site protocols for…
Julie Harlin · TEXAS A&M AGRILIFE RESEARCH · 2021 · $53,536 — Abstract The goal of this project is to develop innovative educational resources aimed at rural middle school-age children and medically underserved populations to increase vaccine confidence and encourage vaccine acceptance by the public. To attain this goal, an interdisciplinary team of scientists…
Donald E Brown · UNIVERSITY OF VIRGINIA · 2021 · $169,903 — Project Summary/Abstract Healthcare interventions and technologies are appropriate and life-changing for some and clearly unethical or physiologically futile for others. The band of uncertainty that lies between these two extremes is a common source of ethical dilemmas in modern healthcare. For abou…
Gautam Gupta · UNIVERSITY OF LOUISVILLE · 2021 · $34,990 — Biomarkers play a central role in the detection, diagnosis, management and monitoring of patients with cancer. Factors such as analytical sensitivity and reproducibility are critical to the clinical utility of plasma-based biomarkers in the setting of longitudinal surveillance and early detection of…
SEAN D SULLIVAN · UNIVERSITY OF WASHINGTON · 2021 · $499,999 — PROJECT SUMMARY The deployment of efficacious SARS-CoV-2 vaccines has prevented the death of millions of people. New SARS- CoV-2 variants that are more transmissible exhibit increased resistance to neutralizing antibodies elicited by either the current vaccine or by prior infection with the original…
Helge Zieler · PRIMROSE BIO, INC. · 2021 · $469,286 — Project Summary/Abstract Messenger ribonucleic acid (mRNA) plays key roles in cells and organisms as a carrier of protein-coding information and as a regulator of gene expression. The pharmaceutical industry has begun to exploit the many natural functions of mRNA to develop novel therapeutics and v…
Jesse Hong-Sae Erasmus · HDT BIO CORPORATION · 2021 · $299,976 — Project summary: First identified in California in 2012, acute flaccid myelitis in children, associated with enterovirus D68 (EV-D68) infection, has been increasing in incidence with outbreaks detected every 2 years. Enteroviruses are well-known causes of central nervous system pathologies, ranging …
Behdad Afzali · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2021 · $3,000,357 — In this year, we extended the concept of cell-autonomous Complement activity as driver of cell behavior into non-immune cells and infection. We found that SARS-CoV-2 infection of respiratory epithelial cells (RECs) also induces Complement gene transcription as one of the top pathways in response to …
Patrick Duffy · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $2,473,905 — In FY2021, LMIV scientists published 1 review article discussing conjugate or particle vaccines. Duffy PE: Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination. Expert Rev Vaccines 2021, 20:185-198. We described the concept and biology behind TBV and provided an upda…
John Tsang · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $68,458 — Our goal is to integrate computational approaches and several cutting-edge high-throughput methods to assess changes in the epigenome, transcriptome, and proteome throughout the course of COVID-19 disease. Using CITE-seq, we will simultaneously interrogate the immune cell surface proteome, transcrip…
William Elkins · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $10,368 — Since early 2020, the Infectious Disease Pathogenesis Section (IDPS) has performed pre-clinical studies and reported the resulting pre-clinical pathology safety and efficacy data to the Vaccine Research Center (VRC), Moderna, and the Food and Drug Administration (FDA). These initial studies involve…
Roger Keith Reeves · HARVARD UNIVERSITY · 2021 · $356,151 — PROJECT SUMMARY/ABSTRACT Advanced Lab Technologies Core (Core I) One of the greatest added values of the Harvard University (HU) CFAR has been accelerated member access to new and emerging technologies. Science is accelerated by changes in technology, and the evolution of flow cytometric, imaging an…
Christina Annunziata · DIVISION OF BASIC SCIENCES - NCI · 2021 · $603,049 — Goal 1: Monocytes It has been shown in mouse models of chemically induced cancer that Interferons (IFNs) are important in the immune-surveillance and immune-editing of tumors. While IFNs alpha (IFNa) and gamma (IFNg) have been shown to have potent anti-neoplastic and anti-proliferative properties in…
ROBERT A SEDER · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $2,490,549 — Mycobacterium tuberculosis (Mtb) is the leading cause of death from infection worldwide. Intradermal (ID) vaccination with BCG has variable efficacy against pulmonary tuberculosis, the major cause of mortality and disease transmission. We showed that the route and dose of BCG vaccination alters circ…
Daniel Cesar Douek · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $3,017,558 — The Genome Analysis Core (TGAC), within the Human Immunology Section, was set up in 2014 to fulfill many of the specialist sequencing needs of the Vaccine Research Center (VRC). Currently, the VRC is designing, producing and testing candidate immunogens aimed at eliciting broadly neutralizing antibo…